Recombinant Rat Siglec-2/CD22 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10572-SL

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10572-SL-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

CHO

Accession #

NP_001100973.1

Conjugate

Unconjugated

Applications

Bioactivity

View all Siglec-2/CD22 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived rat Siglec-2/CD22 protein
Rat Siglec-2/CD22
(Trp24-Gly690)
Accession # NP_001100973.1		 IEGRMDP Mouse IgG2a
(Glu98-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Trp24

Predicted Molecular Mass

102 kDa

SDS-PAGE

112-138 kDa, under reducing conditions

Activity

Measured by the ability of the immobilized protein to support the adhesion of human red blood cells.
The ED50 for this effect is 0.15-1.8 μg/mL.

Scientific Data Images for Recombinant Rat Siglec-2/CD22 Fc Chimera Protein, CF

Recombinant Rat Siglec-2/CD22 Fc Chimera Protein Bioactivity.

Recombinant Rat Siglec-2/CD22 Fc Chimera (Catalog # 10572-SL) supports the adhesion of human red blood cells. The ED50 for this effect is 0.15-1.8 μg/mL.

Recombinant Rat Siglec-2/CD22 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Rat Siglec-2/CD22 Fc Chimera Protein (Catalog # 10572-SL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 112-138 kDa and 220-280 kDa, respectively.

Formulation, Preparation and Storage

10572-SL
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Siglec-2/CD22

Sialic acid-binding immunoglobulin-like lectin 2 (Siglec-2), also known as B-cell receptor CD22 or B-lymphocyte cell adhesion molecule (BL-CAM), is a I-type (Ig-type) lectin belonging to the sialoadhesin subclass of the immunoglobulin superfamily (1). Fourteen human and nine mouse Siglecs have been characterized and are divided into 2 families: CD33 related and evolutionarily conserved (2, 3). The extracellular domain (ECD) of Siglecs are characterized by an N-terminal Ig-like V-type domain, which mediates sialic acid binding, followed by varying numbers of Ig-like C2-type domains (1 -3). The predominant form of human Siglec-2 contains a N-terminal Ig-like V-type domain, six Ig-like C2-type domains, a transmembrane region and a cytoplasmic tail with six tyrosine residues and four immunoreceptor tyrosine-based inhibition motifs (ITIMs) (1-3). A variant form of Siglec-2 missing two Ig-like C2-type domains along with a truncated cytoplasmic tail has also been identified (4). The mature ECD of rat Siglec-2 shares 58% and 76% amino acid sequence identity with human and mouse Siglec-2, respectively. Siglec-2 is an adhesion molecule that preferentially binds alpha 2,6- linked sialic acid on the same (cis) or adjacent (trans) cells (5). Besides its role as an adhesion molecule, Siglec-2 is a coreceptor that physically interacts with B-cell receptor (BCR), negatively regulating BCR signals by recruiting tyrosine phosphatase SHP-1 to its ITIMs. Phosphorylated Siglec-2 can also interact with other intracellular effector proteins such as Syk, PLC gamma, PI3 kinase and Grb-2, suggesting it may play a role in positive signaling (2). Another function of Siglec-2 is that it mediates the anti-phagocytic effect of alpha 2,6-linked sialic acid, and inhibition of Siglec-2 promotes the clearance of myelin debris, amyloid-beta oligomers and alpha -synuclein fibrils in vivo (6). Siglec-2 also plays a role in autoimmunity and has great potential for Siglec-2-based immunotherapeutics for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) (7).

References

  1. Sato, S. et al. (1996) Immunity. 5:551.
  2. Crocker, P.R. and A. Varki (2001) Trends Immunol. 22:337.
  3. Macauley, M.S. et al. (2014) Nature Rev Imm. 14:653.
  4. Stamenkovic, I. and B. Seed (1990) Nature 345:74.
  5. Collins, B.E. et al. (2004) Proc. Natl. Acad. Sci. 101:6104.
  6. Pluvinage, J.V. et al. (2019) Nature. 568:7751.
  7. Clark, E.A. et al. (2018) Front Immunol. 9:2235.

Long Name

Sialic Acid Binding Ig-like Lectin 2

Alternate Names

BL-CAM, CD22, Siglec2

Entrez Gene IDs

933 (Human); 12483 (Mouse); 308501 (Rat); 102130968 (Cynomolgus Monkey)

Gene Symbol

CD22

UniProt

NP_001100973.1

Additional Siglec-2/CD22 Products

Product Documents for Recombinant Rat Siglec-2/CD22 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Rat Siglec-2/CD22 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.